Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New presentation on the website if interested

<< Previous

Bullboard Posts

Next >>

Comment by fasttrack5on Jan 29, 2024 9:36am

464 Views

Post# 35850107

RE:RE:New presentation on the website if interested

canadafan wrote:
The investor presentation has a general new look.
Much more focused.
Specifically notes Roche as collaborator with pending phase 3, alternatively the MBc coterapy TBD.
missing?
No more discussion of Incyte trial or any CAR- t oppotunities.
Future business, which was previously given a broad view of partnerships, licensing etc, now not discussed at all.
The San Diego office still listed under contacts.
Clinically a lot cleaner than previous. Shorter & to the point.
it does say panc phase 3 will start mid 2024.
and MBc phase 3 guidance will be updated also first half of this year as well.
missing?

Details of any business deal to fund the trials?

THAT, is what everyone is waiting for.
and.......yes....clarification of WTF is going on with USA office & footprint.
As I have said, too many times: an answer must come ASAP
My opinion a total buyout is the best overall option.
tick, tick, tick,